Endocrine Ips, Pllc

Houston, Texas 77079

0 studies enrolling now · 14 studies all time

What they study most

CKD, Cardiovascular Diseases, Chronic Kidney Disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathic Pain, Non-alcoholic Steatohepatitis, Obesity, Overweight, Overweight or Obesity, T2D, Type 2 Diabetes

Studies at this site

• A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone — Completed
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain — Stopped early
• A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes — Completed
• A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight — Completed
• A Study of LY3437943 in Participants Who Have Obesity or Are Overweight — Completed
• A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
• Investigational Study of Delayed Release Metformin — Paused
• A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) — Completed
• A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria — Completed
• A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus — Completed
• Mylan Insulin Aspart Study — Completed